Case number 2017-1689
AbbVie Inc. v. Medimmune Limited > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ABBVIE INC. v. MEDIMMUNE LIMITED [OPINION] [precedential] (0) |
| Mar 14, 2018 | 48 | Mandate issued to the United States District Court for the Eastern District of Virginia. Service as of this date by the Clerk of Court. [504925] [JAB] [Entered: 03/14/2018 11:05 AM] (1) |
| Feb 5, 2018 | 47 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (Precedential Opinion). (For the Court: Prost,Chief Judge; Dyk,Circuit Judge and Chen,Circuit Judge). [495008] [SJ] [Entered: 02/05/2018 09:06 AM] (11) |
| Nov 9, 2017 | 46 | Submitted after ORAL ARGUMENT by Jeffrey I. Weinberger for AbbVie Biotechnology, Ltd. and AbbVie Inc. and David I. Berl for Medimmune Limited. Panel: Judge: Prost , Judge: Dyk , Judge: Chen. [474230] [JAB] [Entered: 11/09/2017 10:38 AM] (0) |
| Oct 16, 2017 | 45 | Response to oral argument order from the Appellee Medimmune Limited. designating David I. Berl as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [467900] [Shaun Mahaffy] [Entered: 10/16/2017 10:47 AM] (0) |
| Oct 12, 2017 | 44 | Response to oral argument order from the Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. designating Jeffrey I. Weinberger as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [467486] [Jeffrey Weinberger] [Entered: 10/12/2017 08:07 PM] (0) |
| Sep 21, 2017 | 43 | NOTICE OF CALENDARING. Panel: 1711L. Case scheduled Nov 09, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 203. Response to oral argument order due: 10/16/2017. Arguing counsel is required to check-in at the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [462712] [JAB] [Entered: 09/21/2017 12:45 PM] (0) |
| Jul 17, 2017 | 42 | Notice from Appellee Medimmune Limited regarding conflicts with oral argument (Sept. 5, 2017; Oct. 2, 2017; Nov. 6, 2017; Jan. 8-12, 2018; Feb. 5-9, 2018; Mar. 5-9, 2018). Service: 07/17/2017 by email. [447150] [Shaun Mahaffy] [Entered: 07/17/2017 04:52 PM] (1) |
| May 19, 2017 | 41 | 6 paper copies of the Corrected Joint Appendix [39] received from Appellants AbbVie Biotechnology, Ltd., AbbVie Inc. and Appellee Medimmune Limited. [432875] [KW] [Entered: 05/19/2017 02:31 PM] (0) |
| May 19, 2017 | 40 | Notice from Appellee Medimmune Limited regarding conflicts with oral argument (June 5-9, 2017; September 5-8, 2017; October 2-6, 2017). Service: 05/19/2017 by email. [432694] [Shaun Mahaffy] [Entered: 05/19/2017 09:14 AM] (1) |
| May 16, 2017 | 39 | CORRECTED APPENDIX FILED for AbbVie Biotechnology, Ltd., AbbVie Inc. and Medimmune Limited [38]. Number of Pages: 336. Service: 05/16/2017 by email. The paper copies of the brief should be received by the court on or before 05/24/2017. [432179] [JB] [Entered: 05/17/2017 11:12 AM] (336) |
| May 16, 2017 | 38 | TENDERED from Appellants AbbVie Biotechnology, Ltd., AbbVie Inc. and Appellee Medimmune Limited. Title: CORRECTED JOINT APPENDIX. Service: 05/16/2017 by email. [431972] [Jeffrey Weinberger] [Entered: 05/16/2017 03:14 PM] (336) |
| May 16, 2017 | 37 | Notice of Correction to the Brief Doc No. [30] for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 05/16/2017 by email. [431970] [Jeffrey Weinberger] [Entered: 05/16/2017 03:12 PM] (4) |
| May 15, 2017 | 36 | 6 paper copies of the Joint Appendix [32] received from Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. [431468] [KW] [Entered: 05/15/2017 03:13 PM] (0) |
| May 15, 2017 | 35 | 6 paper copies of the Reply Brief [31] received from Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. [431442] [KW] [Entered: 05/15/2017 02:50 PM] (0) |
| May 12, 2017 | 34 | Notice from Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. regarding conflicts with oral argument (No Conflicts). Service: 05/12/2017 by email. [431153] [Jeffrey Weinberger] [Entered: 05/12/2017 04:18 PM] (1) |
| May 12, 2017 | 33 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 05/19/2017. [430930] [JB] [Entered: 05/12/2017 10:36 AM] (0) |
| May 11, 2017 | 32 | APPENDIX FILED for AbbVie Biotechnology, Ltd. and AbbVie Inc. [30]. Number of Pages: 235. Service: 05/11/2017 by email. The paper copies of the brief should be received by the court on or before 05/19/2017. [430928] This brief has been corrected. See Doc No. [39] [JB] [Entered: 05/12/2017 10:32 AM] (0) |
| May 11, 2017 | 31 | REPLY BRIEF FILED for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. [29]. Number of Pages: 30. Service: 05/11/2017 by email. The paper copies of the brief should be received by the court on or before 05/19/2017. Appendix is due 05/18/2017. [430925] [JB] [Entered: 05/12/2017 10:26 AM] (41) |
| May 11, 2017 | 30 | TENDERED from Appellants AbbVie Biotechnology, Ltd., AbbVie Inc. and Appellee Medimmune Limited. Title: JOINT APPENDIX. Service: 05/11/2017 by email. [430777] This brief has been corrected. See Doc No.[39] [Jeffrey Weinberger] [Entered: 05/11/2017 03:13 PM] (0) |
| May 11, 2017 | 29 | TENDERED from Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Title: REPLY BRIEF. Service: 05/11/2017 by email. [430775] [Jeffrey Weinberger] [Entered: 05/11/2017 03:10 PM] (41) |
| May 11, 2017 | 28 | Statement of Compliance with Fed. Cir. R. 33 for Appellants AbbVie Biotechnology, Ltd., AbbVie Inc. and Appellee Medimmune Limited. Service: 05/11/2017 by email. [430686] [Jeffrey Weinberger] [Entered: 05/11/2017 01:30 PM] (3) |
| May 9, 2017 | 27 | 6 paper copies of the Response Brief [26] received from Appellee Medimmune Limited. [430433] [KW] [Entered: 05/10/2017 04:25 PM] (0) |
| May 1, 2017 | 25 | TENDERED from Appellee Medimmune Limited. Title: RESPONSE BRIEF. Service: 05/01/2017 by email. [428345] [Shaun Mahaffy] [Entered: 05/01/2017 06:30 PM] (73) |
| May 1, 2017 | 26 | BRIEF FILED for Appellee Medimmune Limited [25]. Number of Pages: 59. Service: 05/01/2017 by email. The paper copies of the brief should be received by the court on or before 05/11/2017. Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. reply brief is due 05/15/2017. [429026] [JB] [Entered: 05/04/2017 08:33 AM] (73) |
| Apr 20, 2017 | 24 | Entry of appearance for Shaun P. Mahaffy as of counsel for Appellee Medimmune Limited. Service: 04/20/2017 by email. [425798] [Shaun Mahaffy] [Entered: 04/20/2017 11:01 AM] (2) |
| Apr 13, 2017 | 23 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [423693] [JB] [Entered: 04/13/2017 08:44 AM] (0) |
| Mar 24, 2017 | 22 | 7 paper copies of the Opening Brief [20] received from Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. [419044] [KW] [Entered: 03/27/2017 11:40 AM] (0) |
| Mar 23, 2017 | 21 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Brief Docket No. [19], ERROR: Appellant used abbreviated page ranges when referring to the appendix (Ex. "APPX00190-91" on pg. 8). CORRECTION: When referring to a range of pages in the appendix, both the first and last page in the range should be listed in their entirety (the correct reference for the example would be "APPX00190-91"). Also, pagination must appear centered in the bottom margin of each page in the appendix. For future briefs, please ensure the appendix references are correctly formatted. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [418358] [JB] [Entered: 03/23/2017 01:05 PM] (0) |
| Mar 22, 2017 | 20 | BRIEF FILED for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. [19]. Number of Pages: 58. Service: 03/22/2017 by email. The paper copies of the brief should be received by the court on or before 03/30/2017. Appellee Medimmune Limited brief is due 05/01/2017. [418351] [JB] [Entered: 03/23/2017 12:51 PM] (127) |
| Mar 22, 2017 | 19 | TENDERED from Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Title: OPENING BRIEF. Service: 03/22/2017 by email. [418063] [Jeffrey Weinberger] [Entered: 03/22/2017 04:15 PM] (127) |
| Mar 15, 2017 | 18 | ORDER filed. The motion to expedite proceedings [7] is denied. Service: 03/15/2017 by clerk. [415708] [LMS] [Entered: 03/15/2017 01:58 PM] (2) |
| Mar 13, 2017 | 17 | Docketing Statement for the Appellee Medimmune Limited. Service: 03/13/2017 by email. [415117] [Thomas Fletcher] [Entered: 03/13/2017 10:30 PM] (3) |
| Mar 13, 2017 | 16 | Entry of appearance for Michael A. Morin as of counsel for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 03/13/2017 by email. [414807] [Michael Morin] [Entered: 03/13/2017 12:47 PM] (2) |
| Mar 13, 2017 | 15 | Entry of appearance for David P. Frazier as of counsel for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 03/13/2017 by email. [414802] [David Frazier] [Entered: 03/13/2017 12:41 PM] (2) |
| Mar 10, 2017 | 14 | REPLY of Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. to response filed by Appellee in 17-1689 , Doc. No [13]. Service: 03/10/2017 by email. [414570] [Jeffrey Weinberger] [Entered: 03/10/2017 04:13 PM] (7) |
| Mar 7, 2017 | 13 | RESPONSE of Appellee Medimmune Limited to the motion to expedite appeal [7] filed by Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. in 17-1689. Service: 03/07/2017 by email. [413178] [Thomas Fletcher] [Entered: 03/07/2017 04:37 PM] (11) |
| Mar 7, 2017 | 12 | Certificate of Interest for the Appellee Medimmune Limited. Service: 03/07/2017 by email. [413156] [Thomas Fletcher] [Entered: 03/07/2017 04:15 PM] (3) |
| Mar 7, 2017 | 11 | Entry of appearance for Thomas S. Fletcher as of counsel for Appellee Medimmune Limited. Service: 03/07/2017 by email. [413155] [Thomas Fletcher] [Entered: 03/07/2017 04:13 PM] (2) |
| Mar 7, 2017 | 10 | Entry of appearance for David I. Berl as principal counsel for Appellee Medimmune Limited. Service: 03/07/2017 by email. [413150] [Thomas Fletcher] [Entered: 03/07/2017 04:11 PM] (2) |
| Mar 3, 2017 | 9 | Entry of appearance for Ginger D. Anders as of counsel for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 03/03/2017 by email. [412549] [Jeffrey Weinberger] [Entered: 03/03/2017 06:39 PM] (3) |
| Mar 3, 2017 | 8 | ORDER filed. Any opposition to the motion [7] shall be filed no later than 5:00 p.m. on March 7, 2017. Any reply in support of the motion is due no later than 5:00 p.m. on March 10, 2017. AbbVie’s opening brief is due no later than March 22, 2017. Service: 03/03/2017 by clerk. [412242] [LMS] [Entered: 03/03/2017 09:47 AM] (2) |
| Mar 2, 2017 | 7 | MOTION of Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. to expedite case. Any response is due within 10 days of service [Consent: opposed]. Service: 03/02/2017 by email. [412161] [Jeffrey Weinberger] [Entered: 03/02/2017 08:13 PM] (220) |
| Mar 2, 2017 | 6 | Transcript Purchase Order Form for the Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc. indicating that a transcript is not needed for the appeal. Service: 03/02/2017 by email. [412160] [Jeffrey Weinberger] [Entered: 03/02/2017 08:07 PM] (2) |
| Mar 2, 2017 | 5 | Docketing Statement for the Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 03/02/2017 by email. [412159] [Jeffrey Weinberger] [Entered: 03/02/2017 08:05 PM] (3) |
| Mar 2, 2017 | 4 | Certificate of Interest for the Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 03/02/2017 by email. [412158] [Jeffrey Weinberger] [Entered: 03/02/2017 08:04 PM] (3) |
| Mar 2, 2017 | 3 | Entry of appearance for Heather E. Takahashi as of counsel for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 03/02/2017 by email. [412157] [Jeffrey Weinberger] [Entered: 03/02/2017 08:03 PM] (2) |
| Mar 2, 2017 | 2 | Entry of appearance for Jeffrey I. Weinberger as principal counsel for Appellants AbbVie Biotechnology, Ltd. and AbbVie Inc.. Service: 03/02/2017 by email. [412156] [Jeffrey Weinberger] [Entered: 03/02/2017 08:02 PM] (2) |
| Feb 27, 2017 | 1 | Appeal docketed. Received: 02/24/2017. [410829]Entry of Appearance due 03/13/2017. Certificate of Interest is due on 03/13/2017. Docketing Statement due 03/13/2017. Appellant/Petitioner's brief is due 04/28/2017. [JB] [Entered: 02/27/2017 01:59 PM] (24) |
